Patents by Inventor Basil Rigas

Basil Rigas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240100073
    Abstract: The invention features methods of preventing and/or treating neuropathic pain associated with diabetic peripheral neuropathy (DPN).
    Type: Application
    Filed: November 21, 2023
    Publication date: March 28, 2024
    Inventor: Basil RIGAS
  • Publication number: 20240016799
    Abstract: Compounds of the general Formula A-D-Y are disclosed with activity towards treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. Pharmaceutical compositions, methods of making, and methods of use thereof are also described.
    Type: Application
    Filed: July 20, 2023
    Publication date: January 18, 2024
    Inventor: Basil RIGAS
  • Publication number: 20230293557
    Abstract: The invention relates to compositions and methods for treating ophthalmic conditions.
    Type: Application
    Filed: November 8, 2022
    Publication date: September 21, 2023
    Inventor: Basil RIGAS
  • Patent number: 11752146
    Abstract: Compounds of the general Formula A-D-Y are disclosed with activity towards treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. Pharmaceutical compositions, methods of making, and methods of use thereof are also described.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: September 12, 2023
    Assignee: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil Rigas
  • Publication number: 20220409638
    Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.
    Type: Application
    Filed: June 13, 2022
    Publication date: December 29, 2022
    Inventor: Basil RIGAS
  • Patent number: 11510931
    Abstract: The invention relates to compositions and methods for treating ophthalmic conditions.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: November 29, 2022
    Assignee: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil Rigas
  • Publication number: 20220233556
    Abstract: Methods and compositions that include the use NSAID derivatives for the treatment of dry eye disease, retinopathy, and related diseases are disclosed herein.
    Type: Application
    Filed: December 22, 2021
    Publication date: July 28, 2022
    Inventor: Basil RIGAS
  • Publication number: 20200246330
    Abstract: Compounds of the general Formula A-D-Y are disclosed with activity towards treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. Pharmaceutical compositions, methods of making, and methods of use thereof are also described.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 6, 2020
    Applicant: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil RIGAS
  • Publication number: 20200246359
    Abstract: Methods and compositions that include the use NSAID derivatives for the treatment of disease, retinopathy, and related diseases are disclosed herein.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 6, 2020
    Applicant: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil RIGAS
  • Publication number: 20200237787
    Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.
    Type: Application
    Filed: April 20, 2020
    Publication date: July 30, 2020
    Applicant: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil RIGAS
  • Publication number: 20190343848
    Abstract: The invention relates to compositions and methods for treating ophthalmic conditions.
    Type: Application
    Filed: September 28, 2017
    Publication date: November 14, 2019
    Applicant: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil RIGAS
  • Publication number: 20190307780
    Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.
    Type: Application
    Filed: July 13, 2018
    Publication date: October 10, 2019
    Applicant: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil RIGAS
  • Publication number: 20160243137
    Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also disclosed.
    Type: Application
    Filed: September 18, 2015
    Publication date: August 25, 2016
    Inventor: Basil Rigas
  • Patent number: 9289155
    Abstract: Disclosed is a method and device for detection of H. Pylori in breath emissions utilizing an unlabelled urea, in which a patient ingests a safe quantity of unlabelled urea. After ingestion, expired breath of the patient is analyzed for ammonia, with a detection based on levels of ammonia lower than 50 parts per billion to 500 ppm to detect helicobacter pylori.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: March 22, 2016
    Assignee: The Research Foundation For The State University of New York
    Inventors: Basil Rigas, Anastasia Rigas, Pelagia-Irene Gouma
  • Publication number: 20140315834
    Abstract: The present invention provides novel compounds and pharmaceutical compositions for the prevention and/or treatment of cancer and precancerous conditions thereof, for the treatment of pain and fever, for the treatment of skin disorders, and for treating and/or preventing inflammation-related diseases and/or cardiovascular diseases. The compounds of the invention also have analgesic properties and anti-platelet properties. The compounds of the invention may be provided to animals, including mammals and humans, by administering a suitable pharmaceutical dose in a suitable pharmaceutical dosage form. The compounds of the invention have improved efficacy and safety, including higher potency and/or fewer or less severe side effects, than conventional therapies. The compounds of the invention comprise a biologically active moiety or portion (A) that has, or is modified to have at least one carboxyl group.
    Type: Application
    Filed: September 23, 2013
    Publication date: October 23, 2014
    Applicant: Medicon Pharmaceuticals, Inc.
    Inventor: Basil RIGAS
  • Publication number: 20140178461
    Abstract: Novel compounds and pharmaceutical compositions thereof administered by the respiratory route for prevention and/or treatment of lung and brain cancer and precancerous conditions thereof.
    Type: Application
    Filed: September 23, 2013
    Publication date: June 26, 2014
    Inventor: Basil RIGAS
  • Patent number: 8754047
    Abstract: The present invention provides isolated peptides with at least two cysteine residues capable of forming one or more disulfide bonds. Pharmaceutical compositions comprising the isolated peptides of the present invention are also provided. The invention also provides methods for inhibiting, preventing or improving the pathological or clinical manifestations of cancer or an inflammatory disease or disorder in a subject, comprising administering a peptide of the invention.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: June 17, 2014
    Assignee: The Research Foundation for the State University of New York
    Inventors: Basil Rigas, Yu Sun
  • Publication number: 20140121185
    Abstract: Novel compounds and pharmaceutical compositions thereof for the treatment and/or prevention of cancer and precancerous conditions, inflammation-related disorders, pain and fever.
    Type: Application
    Filed: September 23, 2013
    Publication date: May 1, 2014
    Applicant: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil RIGAS
  • Patent number: 8691764
    Abstract: The present invention provides a method for inhibiting NF-?B activity in a subject, the method comprising providing an agent capable of inducing expression of annexin 1, whereby said agent induces expression of annexin 1 and whereby said induced expression of annexin 1 inhibits NF-?B activity. Also provided are annexin 1 mimetics capable of binding to NF-?B and pharmaceutical compositions of such inducing and mimetic agents.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: April 8, 2014
    Assignee: The Research Foundation for the State University of New York
    Inventors: Zhiquan Zhang, Basil Rigas
  • Publication number: 20140088045
    Abstract: The present invention provides a composition comprising a nicotine-containing material and an anti-cancer agent usable in the treatment and/or prevention or reduction of the risk of cancer and precancerous conditions as well as for preventing or reducing the risk of cancer recurrence. Furthermore, a composition comprising a nicotine-containing material and an anti-inflammatory agent usable in the treatment and/or prevention or reduction of the risk of inflammation, is provided. The nicotine containing composition can also include both an anti-cancer agent and an anti-inflammatory agent A device for administering the composition of the present invention to subjects can be a cigarette, smoking pipe, smokeless tobacco, electronic cigarette, transdermal patch or the like.
    Type: Application
    Filed: August 28, 2013
    Publication date: March 27, 2014
    Inventors: Basil Rigas, Jason B. Rigas